Table 2. Tumor response in the study patients (n = 50).
No. of patients (%) | ||
---|---|---|
Primary site | Overall | |
CR | 5 (10) | 1 (2) |
PR | 35 (70) | 21 (42) |
SD | 4 (8) | 11 (22) |
PD | 0 (0) | 12 (24) |
Not evaluable | 6 (12) | 5 (10) |
Response (CR + PR) | 40 (80) | 22 (44) |
Disease control (CR + PR + SD) | 44 (88) | 33 (66) |